前沿论道|mCRPC骨转移核素治疗新进展—ALSYMPCA研究解读 42972 观看发布时间 2020-08-27 课程介绍 讲者介绍
ALSYMPCA Trial: Updated Analysis of Survival With Radium-223 Treatment in Metastatic Prostate CancerMatthew Stenger
PCN74聽鈥撀燙ost-Effectiveness of Radium-223 Dichloride (Radium-223) In Alsympca: A Cost-Effectiveness Analysis of Radium-223+Best Standard of Care (Bsoc) Compared With Placebo+Bsoc In Treatment of Castration-Resistant Prostate Cancer (Crpc) And Symptomatic Bone Metastases In Canada...
摘要: 770PREASONS FOR PATIENTS (PTS) DISCONTINUING STUDY TREATMENT (TX) IN THE PHASE 3 ALSYMPCA TRIAL OF RADIUM-223 DICHLORIDE (RA-223) IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES (METS)DOI: 10.1093/annonc/mdu336.18 被引量: 1 ...
714 \\{PAIN\\} \\{AND\\} \\{QUALITY\\} \\{OF\\} \\{LIFE\\} (QOL) \\{ANALYSES\\} \\{FROM\\} \\{THE\\} \\{PHASE\\} 3 \\{RANDOMIZED\\} \\{ALSYMPCA\\} \\{STUDY... M Tomblyn,S Nilsson,N Vogelzang,... - 《Journal of Urology》...
Radium-223 prolongs overall survival in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases, regardless of prior docetaxel. Whether or not chemotherapy can be safely administered following radium-223 treatment is of clinical importa...
Chemother- apy following radium-223 dichloride treatment in ALSYMPCA. Prostate. 2016;76:905-16.Sartor, O.; Hoskin, P.; Coleman, R.E.; Nilsson, S.; Vogelzang, N.J.; Petrenciuc, O.; Staudacher, K.; Thuresson, M.; Parker, C. Chemotherapy following radium-223 dichloride treatment in ...
O'Sullivan J, Widmark DCJ, Syndikus I, James N, Dall'Oglio M, et al. Hematologic safety of radium‑223 dichloride (Ra‑223) in the phase 3 ALSYMPCA trial in castration‑resistant prostate cancer (CRPC) patients with bone metastases: b...
Purpose/Objective(s) Radium-223 chloride (Ra-223), a targeted alpha-emitter, is a calcium mimetic that targets bone metastases with high-energy alpha-particles of extremely short range ( < 100 渭m). ALSYMPCA, the phase III, double-blind, randomized, multinational study, was designed to ...
EBRT Use and Safety with Radium-223 in Patients with CRPC and Symptomatic Bone Metastases from the ALSYMPCA Trial Professor Sartor presents results from the ALSYMPCA trial which showed radium-223 significantly reduced the risk of EBRT use for bone pain while significant...